177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

NCT04915144 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Investigator decision

Conditions

Neuroendocrine Tumors
Carcinoid Tumor
Pulmonary Carcinoid Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Vipoma
Insulinoma
Gastrinoma

Interventions

DRUG: 177Lu-DOTATOC

Sponsor

British Columbia Cancer Agency